Entera Bio Ltd. Executive Compensation Details Revealed
Ticker: ENTX · Form: DEF 14A · Filed: Jun 20, 2024 · CIK: 1638097
| Field | Detail |
|---|---|
| Company | Entera Bio LTD. (ENTX) |
| Form Type | DEF 14A |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, sec-filing, DEF14A
TL;DR
Entera Bio Ltd. exec pay for 2023/2022 disclosed, no equity forfeitures.
AI Summary
Entera Bio Ltd. filed a DEF 14A detailing executive compensation for 2023 and 2022. Miranda Toledano served as Executive Officer, with Hillel Galitzer and Dana Yaacov-Garbeli as Non-PEO NEOs. The filing specifies compensation figures as reported in the Summary Compensation Table and adjusted for "compensation actually paid" per Regulation S-K, noting no equity awards were forfeited due to unmet vesting conditions.
Why It Matters
This filing provides transparency into how much top executives at Entera Bio Ltd. were compensated, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine filing disclosing executive compensation and does not present new material risks.
Key Players & Entities
- Entera Bio Ltd. (company) — Filer of the DEF 14A
- Miranda Toledano (person) — Executive Officer
- Hillel Galitzer (person) — Non-PEO NEO
- Dana Yaacov-Garbeli (person) — Non-PEO NEO
FAQ
Who were the Non-PEO NEOs for Entera Bio Ltd. in 2023 and 2022?
Hillel Galitzer and Dana Yaacov-Garbeli served as the Non-PEO NEOs for Entera Bio Ltd. in 2023 and 2022.
What is the purpose of the dollar amounts reported in this filing?
The dollar amounts represent the total compensation reported for each covered fiscal year in the 'Total' column of the Summary Compensation Table and the amount of 'compensation actually paid' as computed in accordance with Item 402(v) of Regulation S-K.
Were any equity awards cancelled due to failure to meet vesting conditions?
No, for the purposes of the equity award adjustments shown, no equity awards were cancelled due to a failure to meet vesting conditions.
What is the filing type and the company's Central Index Key (CIK)?
The filing type is DEF 14A, and the company's CIK is 0001638097.
When is Entera Bio Ltd.'s fiscal year end?
Entera Bio Ltd.'s fiscal year end is December 31st (1231).
Filing Stats: 4,871 words · 19 min read · ~16 pages · Grade level 13.6 · Accepted 2024-06-20 16:07:51
Filing Documents
- zk2431584.htm (DEF 14A) — 951KB
- image00001.jpg (GRAPHIC) — 2KB
- image00002.jpg (GRAPHIC) — 2KB
- 0001178913-24-002017.txt ( ) — 1825KB
- entx-20231231.xsd (EX-101.SCH) — 6KB
- entx-20231231_def.xml (EX-101.DEF) — 5KB
- entx-20231231_lab.xml (EX-101.LAB) — 15KB
- entx-20231231_pre.xml (EX-101.PRE) — 5KB
- zk2431584_htm.xml (XML) — 238KB
SECURITY OWNERSHIP
SECURITY OWNERSHIP 20 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 21 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 22
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 23 PROPOSAL ONE – ELECTION OF DIRECTORS 33 PROPOSAL TWO – RATIFICATION AND APPROVAL OF A ONE-TIME GRANT OF COMPENSATION TO MIRANDA TOLEDANO, OUR CHIEF EXECUTIVE OFFICER AND A DIRECTOR 34 PROPOSAL THREE – RATIFICATION AND APPROVAL OF THE REVISED COMPENSATION TERMS FOR OUR NON-EXECUTIVE DIRECTORS 37 PROPOSAL FOUR – RATIFICATION AND APPROVAL OF THE AMENDMENT TO THE COMPANY'S 2018 INCENTIVE PLAN 39 PROPOSAL FIVE — RATIFICATION AND APPROVAL OF AN AMENDED AND RESTATED COMPENSATION POLICY 41 PROPOSAL SIX — ADVISORY RESOLUTION REGARDING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 43 PROPOSAL SEVEN — ADVISORY RESOLUTION ON THE FREQUENCY OF THE ADVISORY RESOLUTION REGARDING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 44 PROPOSAL EIGHT – APPOINTMENT AND COMPENSATION OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS 45 AUDIT COMMITTEE REPORT 47 WHERE TO OBTAIN ADDITIONAL INFORMATION 48 EXPENSES RELATING TO THIS PROXY STATEMENT 48 48 OTHER BUSINESS 48 PROXY STATEMENT Proxy Statement for Annual Meeting of Shareholders You are receiving this proxy statement and the enclosed proxy card because you owned ordinary shares, par value NIS 0.0000769 per share (the "Ordinary Shares"), of Entera Bio Ltd. (referred to as the "Company," "Entera," "we," "us," or "our"), as of the close of business on Tuesday, June 4, 2024 (the "Record Date"), which entitles you to attend and vote at the 2024 Annual Meeting of Shareholders (the "Annual Meeting"). The Company's board of directors (the "Board") is soliciting proxies from shareholders who wish to vote at the Annual Meeting. By use of a proxy, you can vote even if you do not attend the Annual Meeting. This proxy statement describes the matters on which you are being asked to vote and provides information on those matters so that you can make an informed decision. Important Notice Regar